<DOC>
	<DOCNO>NCT02353871</DOCNO>
	<brief_summary>The purpose protocol demonstrate safety efficacy single treatment injectable liquid form Clostridium botulinum toxin type A haemagglutinin complex ( BTX A HAC ; hereafter refer BTX A HAC Next Generation ( BTX A HAC NG ) ) , use improvement appearance moderate severe glabellar line ( line eyebrows ) .</brief_summary>
	<brief_title>Efficacy Safety Clostridium Botulinum Toxin Type A Improve Appearance Moderate Severe Glabellar Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Provision write informed consent prior study related procedure . Male female 18 65 year age , inclusive . Have moderate severe ( Grade 2 3 ) vertical glabellar line maximum frown baseline ( Day 1 ) , assess ILA use validate 4 point photographic scale . Have moderate severe ( Grade 2 3 ) vertical glabellar line maximum frown baseline ( Day 1 ) , assess SSA use validate 4point categorical scale . Are dissatisfied dissatisfied ( Grade 2 3 ) glabellar line baseline ( Day 1 ) , assess subject 's level satisfaction . Have negative pregnancy test ( female childbearing potential ) . Nonchildbearing potential define post menopausal least 1 year , surgical sterilisation least 3 month enter study , hysterectomy . Have time ability complete study comply study instruction . Previous treatment serotype BTX . Any prior treatment permanent filler upper face include glabellar line area . Any prior treatment long last dermal filler upper face include glabellar line area within past 3 year and/or skin abrasions/resurfacing ( whatever interventional technic use ) within past 5 year , photorejuvenation skin/vascular laser intervention within past 12 month . Any planned facial cosmetic surgery study . A history eyelid blepharoplasty brow lift within past 5 year . An inability substantially reduce glabellar line physically spread apart lack capacity frown . An active infection skin problem upper face include glabellar line area ( e.g . acute acne lesion ulcer ) . Use concomitant therapy , Investigator 's opinion , would interfere evaluation safety efficacy study treatment , include medication affect bleed disorder ( antiplatelet agent and/or anticoagulant give treatment prevention cardiovascular/cerebrovascular disease ) . Pregnant woman , nurse mother , woman plan pregnancy study , believe may pregnant start study . Throughout course study , woman childbearing potential must use reliable form contraception ( e.g . oral contraceptive 12 consecutive week , spermicide condom ) . A history drug alcohol abuse . Treatment experimental drug use experimental device within 30 day prior start study conduct study . Known allergy hypersensitivity serotype BTX component BTX A HAC NG . Clinically diagnose significant anxiety disorder , significant psychiatric disorder ( e.g . depression ) might interfere subject 's participation study . Use medication affect neuromuscular transmission , curare like nondepolarising agent , lincosamides , polymyxin , anticholinesterase aminoglycoside antibiotic , within past 30 day . A history facial nerve palsy . Marked facial asymmetry , ptosis , excessive dermatochalasis , deep dermal scarring , thick sebaceous skin . The presence condition ( e.g . neuromuscular disorder disorder could interfere neuromuscular function ) , laboratory find circumstance , judgement Investigator , might increase risk subject decrease chance obtain satisfactory data achieve objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Moderate Severe</keyword>
</DOC>